Chronogen Names Iraj Beheshti, Ph.D. New President and CEO

Oct 15, 2002, 01:00 ET from Chronogen Inc.

    MONTREAL, Oct. 15 /PRNewswire/ -- Chronogen Inc., a drug discovery company
 developing human therapeutics to treat highly prevalent age-dependent
 diseases, announced today the appointment of Iraj Beheshti, Ph.D., as
 president and Chief Executive Officer.
     "We welcome Iraj to Chronogen," said Siegfried Hekimi, founder and CSO of
 Chronogen and member of its board of directors.  "His experience
 commercializing new technologies is extensive.  His varied experience in both
 management and research makes him the ideal person to lead Chronogen as we
 build our drug discovery capabilities.  He can bring commercial success to the
 vision of harnessing our proprietary Molecular Aging(TM) technology to
 discover therapeutics that will target age-dependent diseases."
     Most recently, Dr. Beheshti served as General Manager of Elitra
 Pharmaceutical's Fungal Research Center in Montreal, Canada.  Prior to joining
 Elitra, Dr. Beheshti served as President and CEO of Mycota Biosciences, before
 Elitra acquired it in 2001.  He has also held various research and management
 positions at Abbott Laboratories, Nymox Pharmaceutical, the clinical
 laboratories at the University of Minnesota Hospital and Clinic, and London
 Diagnostics.  He is a co-inventor on several issued patents relating to
 inventions he made as a founder and president of London Diagnostics.  He has a
 Ph.D. in Organic Chemistry from the University of Sussex, Britain and
 extensive management training from the University of St. Thomas, Minneapolis.
     "I am enthusiastic to be joining Chronogen and I believe the company's
 Molecular Aging technology will enable us to discover the optimal
 interventions to treat highly prevalent age-dependent diseases," commented Dr.
 Beheshti.  "Leading a company with a unique technology to grow and find its
 niche market is a highly rewarding experience, and I look forward to building
 Chronogen as a leading drug discovery company of the diseases of aging
 population."
 
     ABOUT CHRONOGEN
     Chronogen is a privately held drug discovery company developing human
 therapeutics to treat highly prevalent age-dependent diseases, with an initial
 focus on cardiovascular disorders and cancer.  Using its Molecular Aging(TM)
 technologies, the company discovers metabolic pathways whose function is
 related to age-dependent diseases, and identify points along those pathways
 that are ideally suited for drug intervention.  These highly conserved
 pathways are initially identified through the study of C. elegans.  Chronogen
 is headquartered in Montreal, Canada.
 
     For further information please contact Iraj Beheshti of Chronogen Inc.,
 +1-514-918-2633; or Anette Breindl, Ph.D. of Atkins + Associates,
 +1-858-860-0266, ext. 105, abreindl@irpr.com, for Chronogen Inc.
 
                      Make Your Opinion Count - Click Here
                http://tbutton.prnewswire.com/prn/11690X64471817
 
 

SOURCE Chronogen Inc.
    MONTREAL, Oct. 15 /PRNewswire/ -- Chronogen Inc., a drug discovery company
 developing human therapeutics to treat highly prevalent age-dependent
 diseases, announced today the appointment of Iraj Beheshti, Ph.D., as
 president and Chief Executive Officer.
     "We welcome Iraj to Chronogen," said Siegfried Hekimi, founder and CSO of
 Chronogen and member of its board of directors.  "His experience
 commercializing new technologies is extensive.  His varied experience in both
 management and research makes him the ideal person to lead Chronogen as we
 build our drug discovery capabilities.  He can bring commercial success to the
 vision of harnessing our proprietary Molecular Aging(TM) technology to
 discover therapeutics that will target age-dependent diseases."
     Most recently, Dr. Beheshti served as General Manager of Elitra
 Pharmaceutical's Fungal Research Center in Montreal, Canada.  Prior to joining
 Elitra, Dr. Beheshti served as President and CEO of Mycota Biosciences, before
 Elitra acquired it in 2001.  He has also held various research and management
 positions at Abbott Laboratories, Nymox Pharmaceutical, the clinical
 laboratories at the University of Minnesota Hospital and Clinic, and London
 Diagnostics.  He is a co-inventor on several issued patents relating to
 inventions he made as a founder and president of London Diagnostics.  He has a
 Ph.D. in Organic Chemistry from the University of Sussex, Britain and
 extensive management training from the University of St. Thomas, Minneapolis.
     "I am enthusiastic to be joining Chronogen and I believe the company's
 Molecular Aging technology will enable us to discover the optimal
 interventions to treat highly prevalent age-dependent diseases," commented Dr.
 Beheshti.  "Leading a company with a unique technology to grow and find its
 niche market is a highly rewarding experience, and I look forward to building
 Chronogen as a leading drug discovery company of the diseases of aging
 population."
 
     ABOUT CHRONOGEN
     Chronogen is a privately held drug discovery company developing human
 therapeutics to treat highly prevalent age-dependent diseases, with an initial
 focus on cardiovascular disorders and cancer.  Using its Molecular Aging(TM)
 technologies, the company discovers metabolic pathways whose function is
 related to age-dependent diseases, and identify points along those pathways
 that are ideally suited for drug intervention.  These highly conserved
 pathways are initially identified through the study of C. elegans.  Chronogen
 is headquartered in Montreal, Canada.
 
     For further information please contact Iraj Beheshti of Chronogen Inc.,
 +1-514-918-2633; or Anette Breindl, Ph.D. of Atkins + Associates,
 +1-858-860-0266, ext. 105, abreindl@irpr.com, for Chronogen Inc.
 
                      Make Your Opinion Count - Click Here
                http://tbutton.prnewswire.com/prn/11690X64471817
 
 SOURCE  Chronogen Inc.